Text Size
30 studies found for:    Open Studies | "beta-Thalassemia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Beta-thalassemia and Microparticles
Conditions: Thalassemia Major (TM);   Thalassemia Intermedia (TI);   Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
Intervention: Other: Physiopathology
2 Recruiting Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
3 Not yet recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product
4 Recruiting Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia Intermedia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
5 Recruiting Genetic Factors Affecting the Severity of Beta Thalassemia
Condition: Beta Thalassemia
Intervention:
6 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Intervention: Drug: SOTATERCEPT (ACE-011)
7 Unknown † Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
8 Not yet recruiting Post Hematopoietic Stem Cell Transplantation
Condition: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Intervention: Drug: ICL670
9 Not yet recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells
10 Not yet recruiting An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
11 Recruiting Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
Conditions: Transfusional Iron Overload;   Beta-Thalassemia
Intervention: Drug: FBS0701
12 Recruiting ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Condition: Confirmed Diagnosis of ß-thalassemia Major
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
13 Not yet recruiting Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Conditions: Beta-thalassemia Major;   Sickle Cell Disease;   Iron Hemosiderosis
Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670);   Drug: DFP, DFO
14 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
15 Recruiting Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Conditions: Sickle Cell Disease;   Beta Thalassemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
16 Not yet recruiting Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
Condition: Thalassemia Intermedia
Interventions: Drug: Hydroxyurea ,Epiao;   Drug: hydroxyurea, blood transfusion
17 Recruiting Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Conditions: Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune(Registered Trademark));   Alemtuzumab (Campath(Registered Trademark))
Interventions: Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath(Registered Trademark));   Drug: Sirolimus (Rapamune(Registered Trademark));   Drug: Cyclophosphamide (Cytoxan(Registered Trademark));   Procedure: Low Dose Irradiation
18 Not yet recruiting The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Condition: Thalassemia Major
Interventions: Drug: Vitamin D3;   Drug: Placebo
19 Recruiting High-Tc Susceptometer to Monitor Transfusional Iron Overload
Conditions: Transfusional Iron Overload;   Thalassemia Major;   Sickle Cell Disease;   Myelodysplastic Syndromes;   Aplastic Anemia
Intervention: Device: Hepatic biomagnetic susceptibility measurement
20 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
To Top

Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results
† Indicates status has not been verified in more than two years